International trial begins to prevent Alzheimer's in high-risk young adults
An international clinical trial has begun enrolling young adults at high risk for Alzheimer's disease. The study, led by Washington University, aims to prevent the disease by targeting early molecular changes in the brain before symptoms appear. Participants, aged 18 to 25, come from families with genetic mutations linked to early-onset Alzheimer's. They will receive an investigational drug, remternetug, which aims to clear amyloid beta plaques from the brain. This replaces a previously planned drug after its development was halted. The trial will include about 240 participants and last two years, with results expected in four to five years. Funding exceeds $130 million, supported by various organizations, including the National Institutes of Health and the Alzheimer's Association.